ArticleTranslational cancer research2025
Prognostic difference of single metastasis in different sites of hepatocellular carcinoma: a population-based study.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: There is a notable difference in prognosis between single and multiple metastases from hepatocellular carcinoma (HCC). We aimed to identify the prognostic differences among HCC patients with single metastasis to different sites. Methods: The study focused on patients with single metastasis to different organs from HCC from the Surveillance, Epidemiology, and End Results database between 2010 and 2015. We used the Kaplan-Meier method to determine overall survival (OS) and disease-specific survival (DSS). Univariate and multivariate Cox regression analysis, as well as floating absolute risk (FAR), were introduced to compare prognostic differences among the single metastasis. We applied the conditional survival (CS) to calculate the time-varying survival probability. Results: The study included 2,197 individuals. In multivariate Cox analysis, single lung metastasis [hazard ratio (HR) =1.293, 95% confidence interval (CI): 1.053-1.587, P=0.01] was linked to worse OS than single intrahepatic metastasis, while single lung metastasis (HR =1.395, 95% CI: 1.103-1.764, P=0.005) and single bone metastasis (HR =1.306, 95% CI: 1.021-1.67, P=0.03) possessed shorter DSS than single liver metastasis. FAR revealed that OS and DSS for single pulmonary metastasis were inferior to those of bone metastasis. In the subgroup analysis, chemotherapy played an interactive role in the comparison of DSS in single bone metastasis Conclusions: The prognosis of single pulmonary metastasis was worse than that of single bone metastasis and single intrahepatic metastasis. The prognosis of single brain metastasis could not be determined temporarily due to data limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.